Loading patent…
AssigneeAntisense Therapeutics Limited
InventorsChristopher John WRAIGHT, George Arthur Werther, Nicholas M. Dean, Kenneth W. Dobie
Estimating the term…
The present invention provides compositions and methods for modulating the expression of growth factor gene. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding the Insulin Like Growth Factor I receptor (IGF-I receptor or IGF-IR) and in particular human IGF-IR. Such compounds are exemplified herein to modulate proliferation which is relevant to the treatment of proliferative and inflammatory skin disorders and cancer. It will be understood, however, that the compounds can be used for any other condition in which the IGF-IR is involved including inflammatory condition.
1-44. (canceled)
An antisense oligonucleotide comprising 20 to 80 nucleobases in length targeted to a nucleic acid molecule encoding human insulin-like growth factor receptor (IGF-IR), wherein said oligonucleotide specifically hybridizes with said nucleic acid molecule and inhibits the expression of IGF-IR and wherein said oligonucleotide comprises a deoxynucleotide region flanked on both the 5′ and the 3′ ends of said deoxynucleotide region with 2′-O-(2-methoxyethyl) nucleotides.
Dependencies are inferred from the claim text.